Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,560

Document Document Title
WO/2019/110797A8
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...  
WO/2019/176860A1
This cell adhesive material is obtained by modifying a substrate surface by using a peptide group comprising a peptide that contains: 40% to 75%, inclusive, of one or more types of basic amino acid residues selected from the group consis...  
WO/2019/135233A8
Disclosed herein is a process of preparing a polypeptide copolymer by polymerizing a mixture comprising N-carboxyanhydrides of alanine, tyrosine, carboxylate-protected glutamate and an amine-protected lysine, to form a protected polypept...  
WO/2019/135233A1
Disclosed herein is a process of preparing a polypeptide copolymer by polymerizing a mixture comprising N-carboxyanhydrides of alanine, tyrosine, carboxylate-protected glutamate and an amine-protected lysine, to form a protected polypept...  
WO/2019/117274A1
With regard to the present invention, it was discovered that a deprotection agent can be deactivated by a salt formed from a base and an acid having characteristics (i) and (ii), and as a result, excessive elongation of a peptide can be ...  
WO/2019/114159A1
A Camellia Oleifera meal polypeptide as well as a preparation method and an application thereof. The Camellia Oleifera meal polypeptide is prepared by taking Camellia Meiocarpa Hu. meal as raw materials, hydrolyzing the Camellia Meiocarp...  
WO/2019/110774A1
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: a basal insulin having an isoelectric point (pI) of between 5.8 and 8.5; b) and a co-polyami...  
WO/2019/110797A1
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...  
WO/2019/102469A1
Anti-fogging proteinoid compounds are disclosed. Processes of preparing antifogging proteinoid compositions and incorporating thereof in or on a substrate are disclosed. Articles of manufacturing incorporating such compositions are also ...  
WO/2019/088167A1
Provided is a purification agent which comprises a compound having a betaine structure, and which is for a sugar chain having a length equal to or longer than that of a monosaccharide or for a glycopeptide having a sugar chain having a l...  
WO/2019/046699A1
The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor o...  
WO/2019/031446A1
[Problem] To provide a method and a composition for enhancing the immunogenicity of a polypeptide. [Solution] Provided is a composition containing a tagged polypeptide which is composed of a polypeptide, a spacer peptide bonded to a term...  
WO/2019/018238A1
In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). I...  
WO/2018/225864A1
The present inventors found that, in screening a cyclic peptide compound capable of specifically binding to a target molecule, the hitting rate of a cyclic peptide compound capable of specifically binding to the target molecule can be im...  
WO/2018/159797A1
The present invention addresses the problem of providing: an embedding agent for a cell mass or a cell structure which allows the cell mass or the cell structure to be stably transported during transportation at low temperature, and allo...  
WO/2017/124921A9
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...  
WO/2018/140974A1
Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that bin...  
WO/2018/088455A1
To develop a novel biomarker that is useful in diagnosing sepsis and provide a diagnostic agent and diagnostic method therefor. A method for diagnosing sepsis, said method comprising measuring a component selected from carbonic anhydrase...  
WO/2018/088541A1
The present invention provides a drug release means that is capable of independently controlling release of two or more kinds of drugs by supporting the drugs by a hydrogel which contains micelles of a cationic block polypeptide and mice...  
WO/2018/085846A1
The invention relates to multi-functional antibiotic agents formed from antibiotics conjugated to microbial membrane disrupting peptides. These antibiotic-peptide conjugates are designed so that the conjugate simultaneously functions as ...  
WO/2018/075885A1
Supramolecular structures comprising noncovalently associated peptide amphiphiles and lipids are provided. In particular, provided herein are supramolecular nanostructures of peptide amphiphiles and lipids, co-assembly of which is driven...  
WO/2018/057858A1
Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.  
WO/2018/017956A3
Provided are methods for producing recombinant adeno-associated virus (rAAV) vector particles at high recovery or high titer. Also provided are methods that concentrate rAAV vectors to a high concentration, for example, up to 5E+13 (5x10...  
WO/2018/042423A1
The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long ...  
WO/2018/006074A3
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/014841A1
A self-assembled collagen and a preparation method therefor. The preparation method for the self-assembled collagen comprises the following steps: utilizing trypsin and papain in an enzymatic treatment of an animal-derived collagen so as...  
WO/2018/005608A1
In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a t...  
WO/2017/213158A1
The present invention addresses the problem of providing: a ribosome complex which can be prepared without involving a complicated reaction procedure, and in which a presented polypeptide is modified without impairing the function of a r...  
WO/2017/214076A1
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...  
WO/2016/176649A9
The present, invention provides a process for characterizing a glatiramer acetate related drug substance (GARDS) or a glatiramer acetate related drug product (GARDP) comprising separating a batch of a GARDS or GARDP according to hydropho...  
WO/2017/185250A1
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...  
WO/2017/181979A1
Disclosed is a mussel mucin or applications thereof in inhibiting organ inflammation. Specifically disclosed is the mussel mucin or the applications thereof in treating inflammation of the heart, stomach, intestines, lungs, liver, spleen...  
WO/2017/167870A1
The invention concerns a synthetic compound for enabling transfection of eukaryotic cells by means of an amphiphilic block copolymer which synthetic compound comprises a peptide residue having at least one targeting sequence and a nuclei...  
WO/2017/173356A1
Methods and apparatus for identifying and screening hydrogen bond networks are provided. A computing device can determine a search space for hydrogen bond networks related to one or more molecules, where the search space can include a pl...  
WO/2017/155949A1
The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.  
WO/2017/147182A1
Disclosed herein are ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating ...  
WO/2017/124921A1
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...  
WO/2017/124066A1
Described herein are methods of modifying a peptide with a chemical agent. The peptide may be an amphipathic peptide, such as a melittin-like peptide. The reactants are dissolved in an organic solvent and the reaction is allowed to proce...  
WO/2017/101026A1
Disclosed in the present invention is a composition comprising a mussel adhesive protein and a growth factor. The growth factor is selected from platelet growth factors (platelet derived growth factor, PDGF; osteosarcoma derived growth f...  
WO/2017/100697A1
This disclosure relates to specific nanometer-sized nanoparticles made from unmodified dextran (DNPs), DNP conjugates, and related compositions and methods of use.  
WO/2017/096036A1
The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or...  
WO/2017/068577A1
A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.  
WO/2017/070182A1
The inefficient delivery of proteins into mammalian cells remains a major barrier to realizing the therapeutic potential of many proteins. Previously, it has been demonstrated that superpositively charged proteins are efficiently endocyt...  
WO/2016/205902A8
The present invention relates to a novel composition for use in inhibiting or treating microbial biofilm formation, said composition comprising a plant defensin or a peptide derivative thereof and an antifungal compound, preferably caspo...  
WO/2017/046172A1
The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the g...  
WO/2017/045080A1
Functional three-dimensional constructs incorporating biological materials produced by additive manufacturing techniques are provided. The biological material can be a protein that is incorporated into the three-dimensional construct via...  
WO/2017/037196A1
The present invention provides stable pre-fusion class I fusion protein in the pre-fusion conformation, comprising one or more mutations in the hinge-loop that is present between the base helix and the RR1.  
WO/2017/028025A1
Disclosed is a use of a mussel adhesive protein or a preparation thereof for inhibiting a mucosal inflammation. The mucosal inflammation comprises oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheiti...  
WO/2017/028026A1
Disclosed is a use of a mussel adhesive protein or a preparation thereof for mucosal protection, comprising: protecting mucosa from damage caused by ultraviolet, radiation, a high- and low-temperature object, seawater, environmental poll...  

Matches 1 - 50 out of 1,560